More options
Sort by relevance | Sorted by date: newest / oldest | Show use by person

Results 1-20 of 168 for pfizer

Public Bill Committee: Deregulation Bill: Clause 27 - Repeal of power to make provision for blocking injunctions (11 March 2014)

Chi Onwurah: ...in this country and I ask Government Members to recollect that and support measures that seek to protect the important IP that there may be in manufacturing processes, just as in music and pharmaceutical production. I was talking at lunchtime with a Pfizer employee who emphasised the impact that counterfeit medicines, often obtained online, have on its business model and on the health and...

Scottish Parliament: NHS Scotland (2020 Vision) (5 March 2014)

Mark McDonald: ...in Scotland are able to do so. I know that a lot of good work is being done to get more companies to come and view Scotland as an opportunity. I note NRS’s recent announcement that four health boards will become Pfizer INSPIRE—investigator networks, site partnerships and infrastructure for research excellence—sites, which will see them being included among the...

Oral Answers to Questions — Prime Minister: Engagements (27 November 2013) See 1 other result from this debate

Laura Sandys: We are celebrating a year since new owners took over the former Pfizer site, and with the Prime Minister’s commitment to 40 million for our small and medium-sized enterprises in Kent, we now have 1,400 jobs and 60 companies. Does the Prime Minister agree that when the private sector meets a proactive Government, we can replicate such successes around the country?

[Dr William McCrea in the Chair] — Pharmacies and the NHS (20 November 2013)

Jim Shannon: ...are an investment and an essential part of improving patient outcomes. Yet…the proportion of medicines refused by NICE is only increasing.” That is a concern for me, too. Jonathan Emms, UK managing director at Pfizer, has said: “Right now NICE is saying ‘no’ too often. It is blocking many innovative new medicines from reaching the UK patients who need them...

Written Answers — Health: Glaucoma (12 November 2013)

Norman Lamb: ...obtain Xalatan (latanoprost) eye drops through the wholesaler, Alliance Healthcare. Supplies are available. Any pharmacy who experiences difficulties obtaining stock can contact the manufacturer, Pfizer, who will investigate further.

Medicinal Labelling Bill [HL]: Second Reading (25 October 2013)

Lord Winston: ...and critical industries. It is under considerable threat. We have seen a diminution of the pharmaceutical companies in this country. For example, it is very sad for the United Kingdom that Pfizer has moved offshore its research establishment in Sandwich, in Kent. We have lost a great deal of R&D, which is important for that work, and, with it, the trials that might be done. I fear that...

Written Answers — Health: Meningitis: Vaccination (5 September 2013)

Anna Soubry: ...and Immunisation and by the Department. The report was not subject to consultation. Those that made submissions in response to the JCVI call for evidence issued in October 2010 were: Novartis, Pfizer, the Meningitis Trust, the Meningitis Research Foundation and Meningitis UK. The study on meningococcal vaccines referred to on page 22 of the JCVI's minutes from 12 June 2013 was updated at...

Oral Answers to Questions — Treasury: Job Creation (25 June 2013)

Laura Sandys: Does my hon. Friend agree that the combination of an enterprise zone and a regional growth fund that has been supporting jobs in my area following the Pfizer closure, and which the Chancellor very kindly opened, has delivered 750 new jobs in one year? We hope to be announcing a further 200 jobs in the next couple of weeks. Does that sound like a private sector success?

Science and Research — [Martin Caton in the Chair] (4 June 2013)

Julian Huppert: ...becoming more biotech focused. We have to keep the small biotech companies here. When AstraZeneca closed their plant and decided to move to Cambridge, it was a shame for the north-west, but it is fantastic for Cambridge and for the country that it is staying in the UK. It or any other company could choose to leave. Pfizer has a presence in Cambridge, as does GlaxoSmithKline. We have the...

Scottish Parliament: Public Science Engagement Initiatives (21 May 2013)

Jim Eadie: ...companies into Scotland. I will give two further examples from the life sciences. The previous First Minister, Jack McConnell, launched an initiative called the translational medicine research collaboration, which involved the company Wyeth, which is now part of Pfizer. There was significant investment in a collaboration in Scotland that involves four of our universities—the medical...

Scottish Parliament: Electrical Safety in the Private Rented Sector (21 May 2013)

Jim Eadie: ...companies into Scotland. I will give two further examples from the life sciences. The previous First Minister, Jack McConnell, launched an initiative called the translational medicine research collaboration, which involved the company Wyeth, which is now part of Pfizer. There was significant investment in a collaboration in Scotland that involves four of our universities—the medical...

Written Answers — Health: Phenytoin (13 December 2012)

Norman Lamb: ...in the national health service and the manufacturer about the recent increase in the price of phenytoin capsules, following the acquisition of the marketing authorisation by Flynn Pharma Ltd from Pfizer and the effects on NHS budgets.

Previous Business – Lords: Select Committee (20 November 2012)

Science and Technology: Regenerative medicine. 10:30 am; Room 4, Palace of Westminster
Witnesses: (at 10.40am) Dr Ruth McKernan, Chief Scientific Officer of the Neusentis Unit, Pfizer; Professor Chris Mason, Professor of Regenerative Medicine Bioprocessing, UCL; Michael Hunt, Chief Executive Officer, ReNeuron; and (at 11.40am) Navid Malik, Head of Life Sciences Research, Cenkos Security; Nigel Pitchford, Managing Director of Healthcare, Imperial Innovations; and Dr Steven Dyson, Partner...

Scottish Parliament: Christian Aid Tax Justice Bus (14 November 2012)

Neil Findlay: ...;120 billion. That figure is made up of avoidance, evasion and unpaid taxation. The issue is not about small businessmen or sole traders; it is about some of the largest household names and companies such as Pfizer, Starbucks, Google, Facebook, Amazon and Vodafone, to name but a few. A conservative estimate is that those companies are dodging 35 billion every year in unpaid tax to...

Written Answers — Health: Phenytoin (8 November 2012) See 1 other result from this answer

Andrew Stunell: ...of State for Health (1) what estimate he has made of the additional cost to the NHS of the repricing of the epanutin form of phenytoin consequent upon its distribution being transferred from Pfizer to Flynn Pharma; and if he will make a statement; (2) what representations he has received on the decision by Pfizer to transfer the marketing and distribution of the epanutin form of...

Business of the House: Growth and Infrastructure Bill (5 November 2012)

Charlie Elphicke: ...contributions where a business is clamouring for infrastructure to be put in place. For example, the east Kent access extension of the A256 in my constituency cost public funds 87 million, but the contribution from the business that was clamouring for it—Pfizer, which has a plant in Sandwich—was only about 1.6 million. Business is making a very small contribution....

Written Answers — Health: Chemicals: Health Hazards (22 October 2012)

Anna Soubry: ...Ltd, Allschwil, Switzerland Consultant None None Arena Pharmaceuticals, Inc., San Diego, California Astellas Pharma Europe Ltd Daiichi Sankyo, Edison, New Jersey Experimental Pathology Laboratories Inc., Sterling, Virginia ...

Neglected Tropical Diseases (26 June 2012)

Jeremy Lefroy: ...its annual donation of mebendazole to 200 million tablets every year—again, to tackle worms. Novartis is continuing its commitment to providing multi-drug therapy against leprosy in a final push against the disease. Pfizer will continue its donation of drugs for blinding trachoma until at least 2020, as well as donating the drug and a placebo for a study on the reduction in mortality...

Economy: Growth — Motion to Take Note (21 June 2012)

Baroness Sharp of Guildford: ...Yet it is the availability of these highly trained and highly skilled workers that attracts high-value-added foreign investment, such as that in the pharmaceutical industry, and which-note the position of Pfizer-will leave us if we do not maintain the training of a large number of highly qualified people. We may well be ring-fencing science in relation to other public expenditure but we...

Pharmaceutical Industry (21 March 2012) See 4 other results from this debate

Norman Lamb: ...course. We will work closely with the company to secure its support at this very difficult time for the employees affected. The hon. Lady reflected on the closure of AstraZeneca’s Charnwood site in 2010 and the scaling back of Pfizer’s Sandwich site last year, which involved some 1,200 and 2,400 direct jobs respectively. Decisions on how best to respond have to be based to some...

   More options
Sort by relevance | Sorted by date: newest / oldest | Show use by person